β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Open accessThe DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 55 of the 76 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to (1) impact the natural history of β-cell failure; (2) identify and characterize genetic loci for T2D; (3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; (4) develop alternative sources of β-cells for cell-based therapy; (5) focus on metabolic environment to provide indirect benefit to β-cells; (6) improve understanding of the physiology of responses to bypass surgery; and (7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.
Overview
CoChat Summary
TL;DR
This review/consensus report from an international expert meeting argues that progressive β-cell failure is central to type 2 diabetes, involving genetic/epigenetic changes and multiple stressors that lead to dysfunction, dedifferentiation, and death. It concludes existing therapies can improve β-cell function temporarily but generally do not arrest or reverse progression, with possible exception of gastric bypass, and identifies noninvasive β-cell mass measurement and stage-specific/combinatorial interventions as key research needs.
Key findings
- Over 60 genetic loci have been convincingly associated with T2D, the great majority involved in some way in β-cell biology, but these variants explain only a small proportion of total genetic risk; approximately 50% of T2D-associated SNPs introduce or remove a CpG site, suggesting genetic-epigenetic interactions.
- β-cell mass in T2D varies and overlaps with normal individuals, although current data suggest a 20–60% reduction; human β-cell mass varies three- to fivefold unrelated to age or BMI, and insulin sensitivity may vary as much as 10-fold. β-cell function and mass declines are not well correlated, while deteriorating β-cell function is tightly correlated with climbing glucose levels.
- Multiple stressors are implicated: ER stress, metabolic/oxidative stress, amyloid/IAPP oligomers, islet inflammation (IL-1β antagonism can preserve some β-cell functional mass), and disrupted islet integrity. β-cell dedifferentiation has regained favor, and residual β-cells remain even in late disease.
- Interventions show temporary β-cell functional improvement: in the DPP, greater baseline β-cell function and insulin sensitivity independently contributed to restoration of normal glucose tolerance; TZDs improved the oral disposition index; GLP-1–based therapies improve function during treatment but no meaningful persistent change follows withdrawal; RYGB produces disease remission in at least 80% of patients, with duration of diabetes and insulin use before surgery as strongest predictors.
Methods
- Design: narrative review/consensus report from the October 2013 meeting “Beta Cell Failure in Type 2 Diabetes,” cosponsored by the Endocrine Society and the American Diabetes Association, assembling international experts to review the state of the science and identify research needs.
- Data/sample: no primary experimental sample; synthesis of published human and animal studies, including genetics, epigenetics, islet biology, clinical trials, and surgical interventions.
- Analysis: expert discussion and narrative synthesis; future research goals are presented in Table 1 (not included in the provided text).
Limitations
- Stated: studies of epigenetics in T2D are severely limited by the small number of islets available from patients with T2D and by difficulty separating cause and effect in hyperglycemia; human β-cell mass measurement relies entirely on postmortem, cross-sectional assessments, and histomorphometric measurement of β-cell area, volume, and mass is often imprecisely defined and complicated by technical inconsistencies.
- Stated: no study has established whether one pathogenic pathway dominates or can serve as a single major target; durability of β-cell functional improvements following therapy withdrawal remains challenging, and whether earlier intervention can alter the natural history of β-cell failure is unknown.
- Evident from the text: as an expert consensus/narrative review, it does not describe a systematic search strategy or quantitative meta-analysis, and many cited mechanisms and genetic associations remain uncertain or require human validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
35 Valid · 6 Not valid · 7 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“At the time of writing, over 60 genetic loci have been convincingly associated with T2D”
What the sources say
- Disputedcites [8] Voight, 2010, Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis, Nat Genet sourceExperimental — accuracy not yet measured
The Discussion states that the number of confirmed T2D loci stood at 38 when the source paper was written, not over 60. The paper cannot establish a later count at the citing document’s time of writing. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [9] Rosengren, 2012, Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes, Diabetes sourceExperimental — accuracy not yet measured
The source paper's Abstract says recent genome-wide association studies had identified close to 50 loci associated with T2D risk, not over 60. Its count is contrary to the number attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
What the sources say
- Not checked — no full text of the sourcecites [71] Fehse, 2005, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab source
- Disputedcites [73] Bunck, 2011, Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Results (Measures of β-cell function; page unavailable) report a sustained improvement in the disposition index four weeks after exenatide withdrawal, contrary to the categorical claim that none of these agents produced a persistent change. The Conclusions call the effect small and note that it was not enough to sustain glycemic control; the Results (Glycemic control; page unavailable) report that HbA1c and fasting glucose returned to pretreatment values after 12 weeks off treatment. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“further suggest that hyperglycemia alters DNA methylation of PDX1 and INS ( 22 – 25 ).”
What the sources say
- Partly supportedcites [22] Yang, 2012, Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes, Mol Endocrinol sourceExperimental — accuracy not yet measured
The 'Impact of hyperglycemia on DNA methylation of PDX-1' section (page not supplied) reports that HbA1c correlated with PDX-1 methylation in human islets and that high glucose nominally increased Pdx-1 methylation in rat β-cells. The paper does not present a corresponding finding that hyperglycemia alters INS methylation; its Discussion mentions insulin-promoter methylation in patients with type 2 diabetes as a finding from earlier work. (LLM, conf=0.85)
- Supportedcites [23] Yang, 2011, Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets, Diabetologia source
The Discussion reports that 72 hours of hyperglycaemia increased insulin-promoter DNA methylation in clonal rat beta cells, supporting the INS part for which this paper is cited. PDX1 appears only as an insulin-promoter binding-site label in the Results figure caption; this paper is not the source for that part of the multi-citation sentence. (LLM, conf=0.90)
- Could not verifycites [24] Ling, 2008, Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion, Diabetologia sourceExperimental — accuracy not yet measured
The Methods and Results (page not available) examine DNA methylation of PPARGC1A and report higher methylation in diabetic than non-diabetic islets. Searches for PDX1, INS, and hyperglycemia-related methylation found no passage addressing whether hyperglycemia alters methylation of PDX1 or INS. (LLM, conf=0.74)
- Disputedcites [25] Volkmar, 2012, DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients, EMBO J sourceExperimental — accuracy not yet measured
The Results section, “Differential DNA methylation observed in T2D islets is not inducible by high glucose” (page unavailable), reports no significant methylation changes at the tested sites after high-glucose exposure and concludes that T2D-related methylation differences are probably not secondary to hyperglycaemia. It does not report a high-glucose effect on PDX1 or INS specifically, so its findings do not establish the opposite for those two genes; nevertheless, the paper’s stated conclusion runs contrary to the claim attributed to it. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“knockout of miR-375 promotes progressive hyperglycemia in mouse models due to decreased insulin content and progressive loss of β-cell mass ( 32 ).”
What the sources say
- Disputedcites [32] Poy, 2009, miR-375 maintains normal pancreatic alpha- and beta-cell mass, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The Results report hyperglycemia and reduced β-cell mass in miR-375 knockout mice, but the measured mass deficit was 38% at 3 weeks and 31% at 10 weeks, not a progressive loss. The Discussion explicitly attributes their hyperglycemia primarily to an α-cell defect and says the reduction in β-cell mass is unlikely to explain it; plasma insulin was unchanged in these mice. Insulin-deficient diabetes was reported for the separate obese 375/ob model. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Powerful evidence for a genetic component to T2D ( 1 ) has driven extensive efforts to identify genetic variants contributing to risk.”
What the sources say
- Supportedcites [1] Meigs, 2000, Parental transmission of type 2 diabetes: the Framingham Offspring Study, Diabetes source
The paper's Abstract calls type 2 diabetes heritable and says twin concordance, population patterns, and family aggregation support genetic determinants. Its Discussion also considers paternal genetic factors in diabetes risk. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 21 with their cited sources checked
Create a free account to see all 74 claims and every source verdict.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [38]
Experimental — accuracy not yet measured
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336 · cited 1×
“case, these variants explain only a small proportion of total genetic risk (11).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737 · cited 1×
“esis (46), results from a janitorial macrophage infiltration to clear damaged islet b-cells and/or an innate”
BackgroundA pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Self-citationMasters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“levels that allow proapoptotic IAPP oligomers to form (44) that induce interleukin (IL)-1b release to recruit macrophages and enhance local islet inflammation (45).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“GLP-1based therapies magnify glucose-stimulated insulin secretion, as seen with significantly improved β-cell function in T2D following short-term infusions of GLP-1 (68, 69) and longer-”
Influential
Cited by
Items 301–400 of 462
Tong, X., Yagan, M., Hu, R., Nevills, S., Doss, T. D., Stein, R. W., Balamurugan, A. N., & Gu, G. (2024) · Diabetes · doi:10.2337/db23-0528 · Cited by 6
Nagy, L., Béke, F., Juhász, L., Kovàcs, T., Juhász‐Tóth, É., Docsa, T., Tóth, A., Gergely, P., Somsák, L., & Bai, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236081 · Cited by 7
Parra‐Reyna, B., Padilla‐Gutiérrez, J. R., Aceves‐Ramírez, M., Garcia-Garduño, T.-C., Martínez-Fernández, D. E., Jacobo‐García, J. J., Valdés‐Alvarado, E., & Valle, Y. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24529 · Cited by 7
Restored UBE2C expression in islets promotes β-cell regeneration in mice by ubiquitinating PER1
Jiang, H., Zheng, S., Qian, Y., Zhou, Y., Dai, H., Liang, Y., He, Y., Gao, R., Lv, H., Zhang, J., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04868-8 · Cited by 6
Biofluid Proteases Profiling in Diabetes Mellitus
Trindade, F., Ferreira, R. M., Amado, F. M. L., & Vitorino, R. M. P. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.12.004 · Cited by 7
Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications
Eliasson, L., Esguerra, J. L. S., & Wendt, A. (2017) · Diabetology International · doi:10.1007/s13340-017-0304-4 · Cited by 7
Su, H., Ma, X., Shen, Y., He, X., Ying, L., Zhu, W., Wang, Y., Bao, Y., & Zhou, J. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01452-0 · Cited by 6
Alsuhaymi, N., Darwish, A. M., & Khattab, A. E.-N. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06448-0 · Cited by 7
RetractedOxidative Toxicity in Diabetes Mellitus: The Role of Nanoparticles and Future Therapeutic Strategies
Sabahi, M., Ahmadi, S. A., Mahjub, R., & Ranjbar, A. (2019) · Precision Nanomedicine · doi:10.33218/prnano2(4)190809.1 · Cited by 6
“Type 2 diabetes (T2D) is the result of relative degeneration of these cells, caused by multiple issues, such as the failure of peripheral metabolic tissues to respond to insulin action, the liver’s inability to control the production of glucose and the demise of islet βcells (Halban et al., 2014).”
BackgroundLiu, S., Liu, J., Gurung, R. L., Chan, C., Yeo, D., Ang, K., Tang, W. E., Subramaniam, T., Sum, C. F., & Lim, S. C. (2019) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v48n7p217 · Cited by 8
CARD9 Mediates Pancreatic Islet Beta-Cell Dysfunction Under the Duress of Hyperglycemic Stress
Gamage, S., Hali, M., Chen, F., & Kowluru, A. (2022) · Cellular Physiology and Biochemistry · doi:10.33594/000000508 · Cited by 6
Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.
Scheen, A. J. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.56 · Cited by 6
“Whereas type 2 diabetes is characterized by both insulin resistance and defective insulin secretion, an increasing set of data suggests that the defect in insulin secretion plays a prominent role in the development and progression of hyperglycemia (5).”
BackgroundGenome-wide CRISPR Screen Identifies Sec31A as a Key Regulator of Alpha Cell Survival
Shibue, K., Kahraman, S., Castillo-Quan, J. I., Jesus, D. F. D., Hu, J. Y., Morita, H., Blackwell, T. K., Peng, Y., & Kulkarni, R. (2025) · Nature Communications · doi:10.1038/s41467-025-64169-5 · Cited by 6
“In patients with T2D, alpha cell mass is either unchanged or increased 13 – 16 despite chronic exposure to metabolic stressors such as high glucose and/or high free fatty acids, which have deleterious effects on beta cell mass 17 – 20 .”
Biochemical pathways involved in diabetes mellitus
Molehin, O. R., Fakayode, A. E., Olaoye, A. B., Teibo, J. O., & Adeola, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00005-3 · Cited by 8
Rapid Point-of-Care Test for Determination of C-Peptide Levels
Rao, P. V., Bean, E., Nair-Schaef, D., Chen, S., Kazmierczak, S. C., Roberts, C. T., & Nagalla, S. R. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821995557 · Cited by 6
“978 Journal of Diabetes Science and Technology 16(4)”
BackgroundInfluentialLigon, C., Shah, A. M., PRASAD, M. A., & Laferrère, B. (2021) · Diabetes Care · doi:10.2337/dc21-0395 · Cited by 6
Nagao, M., Asai, A., Eliasson, L., & Oikawa, S. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0253 · Cited by 7
Zhang, M., Zhang, S., Yu, Z., Yao, X., Lei, Z., Yan, P., Wu, N., Wang, X., Hu, Q., & Liu, D. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106553 · Cited by 5
Yuan, K., Wu, B., Zeng, R., Zhou, F., Hu, R., & Wang, C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15303 · Cited by 6
“34 Furthermore, higher preoperative β -cell function was significantly associated with a greater likelihood of DR after BMS. 33 Triglyceride glucose (TyG) index, composed of TG and FPG, serve as a composite indicator with high sensitivity and specificity for identifying insulin resistance.”
BackgroundFakhroo, A., Elhadary, M. R., Elsayed, B., Alkuwari, A., Aly, R., Mesilhy, R., Bakalaf, A., Al-Maadhadi, M., Al-Dehaimi, A., Chivese, T., et al. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s428987 · Cited by 10
Guan, J., Abudouaini, H., Lin, K., & Yang, K. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01369-x · Cited by 10
“Some theories posit that stressed β-cells may incite local inflammation in individuals with a genetic predisposition [54, 55].”
BackgroundRetractedEarly beta-cell dysfunction characterizes males with type 2 diabetes of Yemenite origin
Magnazi, M. B., Zornitzki, T., Ulman, M., Madar, Z., & Knobler, H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0838-0 · Cited by 6
Primary Care Endocrinology in the Adult Woman
Thomas, C. C., & Zeytinoglu, M. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.005 · Cited by 4
Gallo, S., Raji, A., Calle, R. A., Pong, A., & Meyer, C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14149 · Cited by 5
Wang, J., Lee, W., Lee, I., Lin, S., Lee, W., Liang, K., Lin, S., & Sheu, W. H. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12784 · Cited by 6
Rohli, K. E., Boyer, C. K., Bearrows, S. C., Moyer, M. R., Elison, W. S., Bauchle, C. J., Blom, S. E., Yu, C.-L., Pope, M. R., Zhang, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.22.461417 · Cited by 5
Kozak, K., & Zajkowska, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199402 · Cited by 7
“This dysfunction is mediated by disturbances in calcium signaling, the buildup of misfolded proteins such as proinsulin and islet amyloid polypeptide, enhanced production of reactive oxygen species, and interleukin-1 β -driven macrophage recruitment [22,23].”
O-glycosylated peptides curtail the aggregation and toxicity of human islet amyloid polypeptide
Zhang, Q., Mei, X., Li, Y., Wang, Z., Li, A., Liu, D., Kumar, S., Kong, D., Hamilton, A. D., & Zhang, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08516-8 · Cited by 5
“…yet, but accumulated evidence has indicated that the development and progression of T2D is highly associated with beta cell failure, which results in the insuf fi cient production of endogenous insulin and lost capability to control blood glucose levels and to counteract insulin resistance 58 .”
Moreno-López, R., Lazaro-Martin, B., Díez, C., Navarro‐Gómez, M. L., & Tarancón‐Díez, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1734023 · Cited by 5
Miyazaki, T., Shirakawa, J., Nagakura, J., Shibuya, M., Kyohara, M., Okuyama, T., Togashi, Y., Nakamura, A., Kondo, Y., Satoh, S., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3060-19 · Cited by 4
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i4.93606 · Cited by 8
Ni, M., Chen, Y., Gu, W., Zhang, Y., Xu, M., Gu, Y., Chen, Y., Zhu, Y., Wang, X. D., Luo, Y., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70090 · Cited by 4
“T2D emerges when pancreatic β-cells are unable to secrete sufficient insulin to overcome peripheral insulin resistance [2, 3].”
Loss of β‐cell identity in human islets treated with glibenclamide
Fernández, C., Nacher, M., Rivera, K., Marín‐Cañas, S., Sorribas, M., Moreno‐González, G., Estil·les, E., José, P. S., Téllez, N., & Montanya, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16632 · Cited by 4
Claes Hellerström and Cartesian diver microrespirometry
Welsh, M. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1109012 · Cited by 4
Zhang, G., Huang, W., An, H., Li, C., & Yu, D. (2017) · International Journal of Electrochemical Science · doi:10.20964/2017.03.04 · Cited by 4
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14383 · Cited by 6
Reflections on the state of diabetes research and prospects for treatment
Accili, D., Du, W. J., Kitamoto, T., Kuo, T., McKimpson, W. M., Miyachi, Y., Mukhanova, M., Son, J., Wang, L., & Watanabe, H. (2022) · Diabetology International · doi:10.1007/s13340-022-00600-2 · Cited by 5
Sithara, S., Crowley, T. M., Walder, K. R., & Aston‐Mourney, K. (2023) · Islets · doi:10.1080/19382014.2023.2165368 · Cited by 5
Principle of Management of Type 2 Diabetes: From Clinical, Public Health and Research Perspectives
Bhattarai, M. D. (2018) · InTech eBooks · doi:10.5772/intechopen.71193 · Cited by 4
Perturbed Mitochondrial Metabolism in Islets from Donors with Type-2 DiabetesPreprint
Sun, J., Jain, R., Andersson, L. E., Medina, A., Storm, P., Spégel, P., & Mulder, H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/212548 · Cited by 4
Lei, X., Chen, X.-F., Qiu, S., Tang, J.-Y., Geng, S., Yang, G., & Wu, Q. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.102994 · Cited by 4
Wu, N., Zhang, W., He, S., Lu, L., Liu, Y.-M., Liu, S., Lei, L., Sun, S., Zhao, Y., Xu, C., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157150 · Cited by 5
Kim, Y., Ha, J., & Moon, J. S. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2026.0034 · Cited by 8
“The etiology of β-cell dysfunction is markedly heterogeneous, reflecting complex interactions between genetic predisposition, ethnic background, and environmental exposures [9].”
Linking Circulating Irisin and Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Aminov, E., Folan, P., & Pisconti, A. (2025) · JCSM Communications · doi:10.1002/rco2.70000 · Cited by 7
Pancreatic β-cell failure in type 2 diabetes mellitus
Kaneto, H. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1123090 · Cited by 4
“Intact β-cells compensate for insulin resistance by augmenting insulin biosynthesis and secretion, but when β-cells are chronically exposed to hyperglycemia, β-cells fail to compensate insulin resistance, which leads to the aggravation of diabetes.[1,2] Such phenomena are well known as pancreatic β-cell glucose toxici…”
BackgroundKawamura, R., Tabara, Y., Takata, Y., Maruyama, K., Takakado, M., Hadate, T., Matsushita, Y., Sano, M., Makino, H., Saito, I., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00523-4 · Cited by 3
Scholz, O., Huß, E., Otter, S., Herebıan, D., Hamacher, A. B., Levy, L. M., Hristeva, S., Sanz, M., Ajani, H., Puentes, A. R., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101775 · Cited by 4
Kaneto, H., Obata, A., Shimoda, M., et al. (2023) · Journal of Diabetes Research · doi:10.1155/2023/8803172 · Cited by 3
Precision Nutrition in Diabetes
Garg, R., & Heber, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15315-0.00016-x · Cited by 4
Nema, P., Agarwal, S., Kori, S. K., Kumar, A., Kashaw, V., Soni, V., Iyer, A. K., & Kashaw, S. K. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00701-6 · Cited by 3
Insulin sensitizer prevents and ameliorates experimental type 1 diabetes
Valitsky, M., Hoffman, A., Unterman, T. G., & Bar‐Tana, J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2016 · Cited by 4
Camilo, D. F., Vasques, A. C. J., Hayashi, K., Tura, A., da Silva, C. D. C., Zambon, M. P., Antonio, M. Â. R. D. G. M., & Geloneze, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.013 · Cited by 3
Ofori, J. K., Malm, H. A., Mollet, I. G., Eliasson, L., & Esguerra, J. L. S. (2017) · PeerJ · doi:10.7717/peerj.3503 · Cited by 4
Li, Y., Sheu, W. H., Lee, W., Lee, I., Lin, S., Lee, W.-L., Liang, K., & Wang, J. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0846 · Cited by 4
Molecular aspects and biochemical regulation of diabetes mellitus
Gyamfi, D., Awuah, E. O., & Owusu, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-849886-6.00002-1 · Cited by 9
Emery, A., Ye, C., Choi, H., Kramer, C. K., Zinman, B., & Retnakaran, R. R. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0111 · Cited by 4
Kalra, S., & Gupta, Y. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.51 · Cited by 3
Fisher, C., Johnson, K., Moore, M. N., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.06.556526 · Cited by 3
“Clinical evidence suggests a progressive agedependent decline in β-cell function during T2DM, including loss of glucose-mediated insulin secretion in the pancreas(26), which is largely dependent on controlled expression and function of KATP channels(27).”
BackgroundFu, W., Lu, R., Wang, D., & Sang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110044 · Cited by 4
Bogdanović, J. M., Babić, I., Gajović, J. S., Lukač, S. S., Mijac, D. D., Popovic, D. D., Ranković, I., Popović, L., Rasulić, I., & Lalic, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115124 · Cited by 2
“Initially, pancreatic β -cells compensate by increasing insulin secretion, but chronic glucotox-icity, lipotoxicity, oxidative and endoplasmic reticulum (ER) stress lead to β -cell dysfunction, loss of mass, and apoptosis, driving the transition to overt hyperglycemia [16–19].”
Cardiovascular outcome trials in type 2 diabetes: A critical analysis
Ashraf, H., & Ahmad, J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.001 · Cited by 3
Antidiabetic agents: Do they hit the right targets?
Zhao, Y., Zhang, X., Liang, H., & Wang, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0030 · Cited by 2
Yadav, M., & Akhter, Y. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30511 · Cited by 2
“6,7 Therefore, to better understand the mechanism of T2DM and reduce the complications of T2DM, it is especially important to clarify the regulatory mechanism of insulin secretion and beta ‐ cell dysfunction at the structural level.”
BackgroundElliott, J. A., & Reynolds, J. V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00013-9 · Cited by 2
Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes
Dalle, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126425 · Cited by 4
Bakterielle kutane Infektionen bei Diabetes mellitus und Behandlung
Makrantonaki, E., Kostaras, S., & Zouboulis, C. C. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05441-5 · Cited by 3
Mettl3 deficiency leads to impaired insulin secretion via regulating Ire1a of mature β-cells in mice
Zhang, X., Shan, A., Chen, J., Cao, Y., & Jiang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-93799-4 · Cited by 4
Khalil, M. I., Monfared, A. L., & Mahmood, H. B. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_74_24 · Cited by 3
“T2DM is a metabolic disorder characterized by hyperglycemia resulting from the dysfunction of pancreatic β-cells (36).”
Zinevich, T. V., Maslov, I. O., Kirichenko, O. G., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050642 · Cited by 2
“Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disease characterised by hyperglycaemia arising from both insulin resistance [1] and impaired insulin production [2].”
Bridging pancreatic and hepatic development: overlapping genes and their role in diabetes
Ghanem, S. S., Al-Barazenji, T., Badi, R. M., & Abdelalim, E. M. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00790-y · Cited by 8
Reduced blood glucose through thyroid hormone degradation product
Eliasson, L. (2016) · Acta Physiologica · doi:10.1111/apha.12847 · Cited by 2
“In practice, the hyperglycaemia is due to insulin resistance and failure of the insulin-secreting beta cells to adjust to the increased metabolic demand (Halban et al. 2014).”
BackgroundStratifying Diabetes: Desperately Seeking Specificity
Leslie, R. D., & Jerram, S. T. (2017) · Diabetes · doi:10.2337/dbi16-0074 · Cited by 2
Hartley, A., Haskard, D. O., & Khamis, R. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.003 · Cited by 4
“This gives some plausible support to the controversial notion of loss of beta-cells in diabetes being a consequence of metabolic stress inducing cell-driven apoptosis (Halban et al., 2014).”
BackgroundMedical Herbs and the Treatment of Diabetes Mellitus: Mechanisms of Action
McGrowder, D. A., Miller, F. G., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Anderson-Jackson, L., Williams, L., & Alexander-Lindo, R. L. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-4808-0.ch003 · Cited by 2
Aldo-ketoreductase 1c19 ablation does not affect insulin secretion in murine islets
Miyachi, Y., Kuo, T., Son, J., & Accili, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260526 · Cited by 2
Kowluru, A., Gamage, S., Hali, M., & Gleason, N. F. (2022) · Cellular Physiology and Biochemistry · doi:10.33594/000000557 · Cited by 2
“Several underlying signaling pathways have been proposed, including induction of apoptotic genes, in the cascade of events leading to dysfunction of the islet beta cells under metabolic stress [11-16].”
Magalhães, A., Barra, C., Borges, A., & Santos, L. C. (2022) · Diabetology · doi:10.3390/diabetology3040046 · Cited by 5
Mitrea, A., Vladu, I. M., Rosu, M. M., Clenciu, D., Moța, E., & Moța, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002510 · Cited by 2
Lee, J., Choi, S.-B., Sung, D.-J., Jin, M., Lee, J. H., Mun, J.-Y., Hwang, T.-S., Han, S.-D., Ro, Y., Kim, S. Y., et al. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.2.114 · Cited by 2
“To mimic end-stage diabetes, in which loss of -cell function and mass is significant (12), subtotal-pancreatectomy (subtotal-Px) was performed in rats.”
BackgroundUclés, R. M. (2018) · Louisiana State University · doi:10.31390/gradschool_dissertations.4802 · Cited by 2
Nema, P., Agarwal, S., Kori, S. K., et al. (2023) · Preprints.org · doi:10.20944/preprints202310.0396.v1 · Cited by 2
Sokolowski, E. K., Kursawe, R., Selvam, V., Bhuiyan, R. M., Thibodeau, A., Zhao, C. G., Spracklen, C. N., Ucar, D., & Stitzel, M. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.17.580646 · Cited by 2
MicroRNAs in Type 2 Diabetes: Focus on MicroRNA Profiling in Islets of Langerhans
Cowan, E., Karagiannopoulos, A., & Eliasson, L. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2807-2_8 · Cited by 1
McCarthy, K. J., Liu, S. H., Kennedy, J., Chan, H. T., Mayer, V., Vieira, L., Glazer, K. B., Wye, G. V., & Janevic, T. M. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae219 · Cited by 3
Kitamura, A., Kurajoh, M., Miki, Y., Kakutani, Y., Yamazaki, Y., Ochi, A., Morioka, T., Mori, K., Shoji, T., & Emoto, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14279 · Cited by 4
“In addition to insulin resistance noted in affected individuals, type 2 diabetes is a metabolic disease characterized by impaired insulin secretory capacity as a result of b -cell dysfunction 1 .”
BackgroundMiskiv, V., Kogut, A., Zhurakivska, О. Y., et al. (2025) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.1(152).2025.61-68 · Cited by 1
Fu, Q., Dai, H., Wang, J., Liu, L., Silva, L. F., Jiang, H., Yu, Q., Fu, Z., Peng, R., Xia, Z., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf372 · Cited by 1
Peptides from Animal Venoms: A Promising Frontier in Diabetes Therapy via Multi-Target Mechanisms
de Almeida, J. O. C. S., Comerma-Steffensen, S., Leite, J. R. S. A., Simonsen, U., & Arcanjo, D. D. R. (2025) · Pharmaceuticals · doi:10.3390/ph18101438 · Cited by 2
“Furthermore, determining whether Jingzhaotoxins can promote beta cell growth, proliferation, and protection against apoptosis is particularly relevant given that T2DM progression is associated with beta cell death and reduced insulin secretion [42–44].”
Kaneto, H., Kimura, T., Sanada, J., Iwamoto, Y., Shimoda, M., Nakanishi, S., & Kaku, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70165 · Cited by 1
Free Sugars Consumption and Type 2 Diabetes: What Are the Concerns and How Strong is the Evidence?
Louie, J. C. Y., & Tan, S. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00740-w · Cited by 5
Investigational treatments of β-cell failure and replacement
Accili, D., Du, W., Kitamoto, T., McKimpson, W. M., Son, J., & Watanabe, H. (2026) · Diabetology International · doi:10.1007/s13340-026-00878-6 · Cited by 1
Popovic, D. S., Koufakis, T., Vas, P. R. J., Prato, S. D., & Παπάνας, Ν. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70631 · Cited by 1
“However, a strict demarcation of these two entities is much less straightforward in clinical settings, with many individuals exhibiting overlapping features (e.g., simultaneous presence of autoimmune markers and insulin resistance, obesity and early β-cell failure, etc.) [2–5].”
The metabolic-inflammatory axis in aging: A multi-organ framework anchored in Sarcopenia — A review
Liang, T. (2026) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2026.106254 · Cited by 3
Insulin/IGF signaling in islet biology and its therapeutic implications
Kim, H., & Kulkarni, R. N. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag014 · Cited by 2
Role of Proteases in Diabetes Mellitus
Ghosh, S., Pandey, B., & Sil, P. C. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_20 · Cited by 1
An Immersible Microgripper for Pancreatic Islet and Organoid Research
Früh, E., Bütefisch, S., Gursky, B., Brüning, D., Leester-Schädel, M., Dietzel, A. H., & Rustenbeck, I. (2022) · Bioengineering · doi:10.3390/bioengineering9020067 · Cited by 1
“The research on pancreatic islets is of major importance to the development of more effective treatments for diabetes mellitus, a chronic metabolic disease that causes hardship and suffering on a worldwide scale [13].”
BackgroundCOMBINSI (COMBat to INSufficient Insulin therapy) – A Portuguese project in type 2 diabetes
de Carvalho, F. S., Marques, F. D. B., Ferreira, J. L., Lopes, A. E., & Príncipe, R. M. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102776 · Cited by 2
Triplitt, C. L., Cersósimo, E., Alatrach, M., Adams, J. M., HANSIS-DIARTE, A. A., Baskoy, G., Gastaldelli, A., Chavez-Velazquez, A., & DeFronzo, R. A. (2025) · Diabetes Care · doi:10.2337/dc25-0490 · Cited by 3
Satin, L. S., Ha, J., & Sherman, A. (2016) · Diabetes · doi:10.2337/dbi16-0025 · Cited by 1
Metadata
- Authors
- Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
- Affiliations
- University of Geneva (CH)
- University of Chicago (US)
- Wake Forest University (US)
- Albert Einstein College of Medicine (US)
- Lund University (SE)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Columbia University (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Halban, Philippe A.
- Polonsky, Kenneth S.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1751-1758
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4179518
- OpenAlex
- W2142418958
- Semantic Scholar
- b30b808a69da53c538eed4ffb6c8ae812e4bfe16
- Cited by
- 460
- References
- 91
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 30 · 2023: 38 · 2022: 41 · 2021: 37 · 2020: 49 · 2019: 50 · 2018: 46 · 2017: 57 · 2016: 29 · 2015: 30 · 2014: 3
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- University of Pennsylvania
- University of Washington
- University of Exeter
- Vrije Universiteit Amsterdam
- Lunds Universitet
- Novo Nordisk
- Università di Pisa
- Novo Nordisk Fonden (NNF11OC1014546)
- National Institutes of Health (UL1TR000430)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082590, P30DK020593, P30DK020595)
- National Center for Advancing Translational Sciences
- Children's Hospital of Pittsburgh
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- beta-cell failure, type 2 diabetes, beta-cell dysfunction, beta-cell mass, genetic susceptibility, diabetes prevention, diabetes treatment, genetic loci, cell therapy, bariatric surgery, circulating factors
- MeSH terms
- Congresses as Topic, Diabetes Mellitus, Type 2, Expert Testimony, Humans, Signal Transduction, Genetic Predisposition to Disease, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.